Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635 1636 1674
This examiner grants 75% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18287909 | MATERIALS AND METHODS FOR IMPROVING EFFICACY OF ADOPTIVE IMMUNE CELL THERAPY | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18340582 | GENETIC ELEMENTS DRIVING CIRCULAR RNA TRANSLATION AND METHODS OF USE | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18510900 | Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17622048 | NEURODEGENERATIVE DISEASE THERAPIES UTILIZING THE SKIN-BRAIN AXIS | Non-Final OA | Ohio State Innovation Foundation |
| 18622162 | METHOD FOR MODULATING UNPRODUCTIVE ALTERNATIVE SPLICING | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18246594 | PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17905285 | METHOD FOR DIAGNOSIS AND/OR PROGNOSIS OF LIVER DISEASE PROGRESSION AND RISK OF HEPATOCELLULAR CARCINOMA AND DISCOVERY OF THERAPEUTIC COMPOUNDS AND TARGETS TO TREAT LIVER DISEASE AND CANCER | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18036022 | METHODS FOR INHIBITING CHMP7 EXPRESSION IN NEURONAL CELLS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18316981 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY | Final Rejection | University of Virginia Patent Foundation |
| 18306680 | THERAPEUTIC TARGETING OF ACTIVATED AVIL-INDUCED SARCOMAS | Final Rejection | University of Virginia Patent Foundation |
| 18605332 | ENZYMATIC METHODS AND COMPOSITIONS FOR POLYMERIZATION OF PHOSPHORAMIDATE AND THIOPHOSPHORAMIDATE-LINKED DNA | Non-Final OA | The General Hospital Corporation |
| 18485352 | COMPOSITIONS USEFUL FOR TREATING SPINAL AND BULBAR MUSCULAR ATROPHY (SBMA) | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18248982 | NOVEL RNA COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL3 | Final Rejection | SANOFI |
| 17638339 | COMPOSITIONS AND METHODS FOR INHIBITING PCSK9 | Non-Final OA | SANOFI |
| 18009069 | USE OF MICRO-RNA TO IMPROVE AND TREAT CHRONIC PHASE CARDIAC FUNCTION | Non-Final OA | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM |
| 18434928 | COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 18376217 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18548634 | DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC |
| 18136386 | MUCIN 5B (MUC5B) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17683423 | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 18012031 | METHODS AND COMPOSITIONS FOR EDITING THE B2M LOCUS IN B CELLS | Final Rejection | SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) |
| 18287150 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF H-ABC LEUKODYSTROPHY | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 17869611 | METHODS FOR LABELING AND TARGETING CELLS | Final Rejection | Whitehead Institute for Biomedical Research |
| 18027293 | METHODS FOR TREATING NEUROLOGICAL DISEASE | Non-Final OA | ASKBIO INC. |
| 17798339 | RNAS FOR COMPLEMENT INHIBITION | Final Rejection | Apellis Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy